Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azvudine and Aluvia drug interaction study in healthy volunteers
NCT07002242Phase 1Completed
- Sponsor
- Genuine Biotech
- Start
- Jul 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azvudine (3 arms), sponsored by Genuine Biotech. Primary endpoints: Maximum Plasma Concentration at Steady State at 27 days, Time to Maximum Plasma Concentration at Steady State at 27 days and 1 more. Started Jul 2022; status: completed.
02
Drugs
azvudine
Beyond the preview
Go deeper on NCT07002242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07002242.